Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tropical diseases
Biotech
Merck admits defeat in chikungunya vaccine race with Valneva
Once competing with Valneva to get a chikungunya shot to market, it looks like Merck & Co. has admitted defeat as its rival reaches the finish line.
James Waldron
Feb 2, 2023 11:07am
Racing resistance, Novartis plans pivotal malaria drug trial
Nov 23, 2022 7:20am
Novartis, GSK commit $1.25B to tropical disease R&D
Jun 23, 2022 5:52am
Valneva exceeds protection goal in chikungunya vaccine trial
Aug 5, 2021 7:40am
Takeda’s dengue shot keeps 84% of kids out of hospital
May 23, 2021 11:49pm
Gates, Merck and Novartis-backed Adjuvant Capital raises $300M
Feb 18, 2021 7:45am
